In addition, through the inhibition of Lck and Fyn, TG02 reversed the BCR-mediated activation of NF-κB, SYK, and Akt, an action to abrogate the protection of CLL cells by the microenvironment. This evidence concerns the gene AKT1 and B-cell chronic lymphocytic leukemia.